It’s always a good idea to keep track of analyst upgrades.
Just don’t rely solely on their arguments as a reason to buy anything. Be sure to do your own due diligence with the company’s fundamental and technical pivot points first.
That being said, here’s what analysts like at the moment.
Nvidia (SYM: NVDA)
Analysts at Bernstein reiterated an outperform rating on Nvidia (NVDA) as it heads into earnings. The firm cited NVDA’s data center opportunity as a key driver.
Just yesterday, Goldman Sachs raised its price target on Nvidia to $200 from $185, with a buy rating. As noted by CNBC, “Analyst James Schneider said that even though investor expectations are high heading into fiscal second-quarter results at the end of August, the chipmaker should have no trouble rising to the occasion.”
In addition, according to Mizuho Securities, the NVDA dip following earnings from Super Micro Computer and Advanced Micro Devices is a buying opportunity.
Peloton (SYM: PTON)
Goldman Sachs also upgraded Peloton (PTON) to a buy rating, citing a turnaround at the company.
The firm raised its PTON price target to $11.50, noting, ““n total, we see PTON as a story with new [management], new initiatives aimed at platform growth and monetization for the next few years and a scope for higher incremental returns on capital in the form of free cash flow conversion,” as quoted by CNBC.
Live Nation (SYM: LYV)
Goldman Sachs also reiterated its buy on Live Nation (LYV).
“We reiterate our Buy rating on shares of Live Nation and increase our Price Target to $168 ($162 prior) following 2Q25 results that featured better than expected performance in Concerts, and ~in-line Sponsorships & Ticketing,” as quoted by CNBC.
Bonus: Chart of Day
D-Wave Quantum (SYM: QBTS)
QBTS could see higher highs with growing quantum computing optimism.
Plus, most recently, Bank of America said quantum computing could be “humanity’s biggest breakthrough since the discovery of fire.”
B. Riley’s just raised its QBTS price target to $22 a share, with a buy rating. Analysts at Canaccord initiated coverage with a buy rating and a price target of $20 a share, with more price upgrades likely, as quantum computing revolutionizes just about everything.
Such technology could even be used to discover new drugs, quicker than even imagined. For example, according to ZDNet.com, the discovery of new drugs relies on molecular simulation, which is complex and time-consuming with all of the calculations needed.
Quantum computing may even be able to help advance artificial intelligence, machine learning, financial modeling, cybersecurity, batteries, and even help with green energy.
Today's Bonus Content: Future AI: Robot Life Partners?
Musk: My new robots could be bigger than Tesla
With DOGE, Elon Musk isn’t afraid of controversy.
But has he finally gone too far?
He’s introduced new, humanoid Optimus robots.
They’ll soon be building Teslas…
But that’s not all they’ll do.
Musk also mentioned these AI-brained robots…
Could serve as “romantic companions” for lonely people.
(Except the words he used were more explicit.)
Is this the future of AI?
No one should bet against Musk.
Found this helpful? Share it with others.
Written by Ian Cooper